Novo Nordisk A/S – Positive CHMP Recommendation for Wegovy 7.2 mg
The Danish pharmaceutical company Novo Nordisk A/S received a favourable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 22 May 2026 regarding its new formulation of Wegovy. The recommendation covers a 7.2 mg single‑dose pen that delivers a weekly injection of semaglutide for the treatment of obesity.
Key Points of the CHMP Recommendation
| Item | Detail |
|---|---|
| Product | Wegovy 7.2 mg, single‑dose pen |
| Indication | Obesity |
| Efficacy | Mean weight loss of 20.7 % in clinical trials |
| Administration | Weekly injection via a single‑dose pen |
| Recommendation | Positive opinion for EU market approval |
| Source | European Medicines Agency, CHMP (Committee for Medicinal Products for Human Use) |
The recommendation follows the earlier approval of Wegovy in 2021 and confirms the company’s position as a leading developer of GLP‑1 receptor agonists for weight management.
Market Reaction
Shares of Novo Nordisk A/S (NVO) were quoted at 289 DKK on 21 May 2026, reflecting a market capitalization of approximately 1.28 trillion DKK. The news of the CHMP recommendation was received positively by investors, with a noticeable uptick in trading volume. The company’s share price has remained within the 52‑week range of 224.25 DKK (lowest) to 533.4 DKK (highest).
Company Context
Novo Nordisk operates in two main segments:
- Diabetes Care and Obesity – including its flagship drug, Wegovy, which has become a central revenue driver.
- Biopharmaceuticals – focused on innovative therapies in other therapeutic areas.
With a price‑earnings ratio of 10.54, the company is considered reasonably valued relative to its earnings potential. The firm’s ongoing investment in artificial intelligence to accelerate drug development, as announced on 22 May 2026, underscores its commitment to maintaining a competitive edge in the obesity treatment market.
Outlook
The CHMP recommendation is a critical step toward EU approval, which will allow Novo Nordisk to expand its market presence and potentially increase revenue from obesity treatments. The company’s strategic focus on AI‑driven drug discovery and its robust pipeline position it well for sustained growth in the pharmaceutical sector.
All information is based on the provided financial and news sources.
